The Non-Invasive Hemodynamic Monitoring System market is expected to experience unprecedented growth by 2030, according to a comprehensive report by Coherent Market Insights [0848c9a9]. The report provides a detailed analysis of the market, including growth factors, trends, opportunities, and the competitive landscape. It offers valuable insights and recommendations for stakeholders, covering potential market segments, business strategies of industry players, investment opportunities, and current trends. The report includes Porter's Five Forces analysis and explores the competitive landscape, providing country-level data for various countries. Additionally, it evaluates leading manufacturers in the market and provides company profiles. The report also predicts the growth and demand forecast for several other markets, including the Predictive Analytics Market, Ambient Intelligence Market, X-ray Detectable Gauze Sponges Market, Orthopedic Bone Cement and Casting Materials Market, and Bladder Cancer Therapeutics Market [0848c9a9].
In addition to the Non-Invasive Hemodynamic Monitoring System market, the Home Blood Glucose Monitor market is also expected to witness significant growth. A research report by The Meade County Messenger highlights the growth trends and competition in the Home Blood Glucose Monitor market. The report discusses key players in the market, including Ascensia Diabetes Care, Demant, Dexcom, and F. Hoffmann-La Roche Ltd. It provides insights into the market's growth potential, trends, and competitive landscape. The report offers valuable information for stakeholders, including investors, manufacturers, and healthcare professionals. With the increasing prevalence of diabetes, the demand for home blood glucose monitors is expected to rise. These devices allow individuals to monitor their blood glucose levels conveniently at home, improving their management of diabetes. The report predicts significant growth in the Home Blood Glucose Monitor market, presenting opportunities for market players to expand their product offerings and cater to the growing demand [85598f14].
Swiss deep-tech startup Spiden has achieved a significant scientific milestone in non-invasive glucose sensing, attaining a 9% MARD with individual calibration. The company has commenced measurements in diabetes centers in multiple countries and aims to launch its Spiden wearable that can automatically calibrate to its customers without any needle involved. Spiden plans to launch its own glucose monitoring wearable by the end of 2025 and expand to additional biomarkers. The company has added key executives to its leadership team, including Chester Chipperfield as Chief Design Officer, Ismene Grohmann as Chief Product Officer, and Prof. Fernando Perez-Cruz as Head of Machine Learning Research & AI. Spiden has secured $15 million in additional funding, surpassing its initial target of $10 million, bringing its total funding since inception to over $40 million. The funding will help Spiden finalize its R&D phase and secure a pathway to miniaturization of its portable product to a wearable format. A larger funding round is planned for H2 2024. [fb868f38]